Original Article |
Corresponding author: Yordan S. Ivanov ( dr_iordan_ivanov@abv.bg ) © 2023 Yordan S. Ivanov, Tsvetan Tsenkov.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Ivanov YS, Tsenkov T (2023) Functional results after reconstruction with modular tumor endoprostheses in patients with malignant bone tumors. Folia Medica 65(1): 80-86. https://doi.org/10.3897/folmed.65.e75380
|
Introduction: The functional outcome in patients after limb salvage surgery, and in particular reconstructions with modular tumor endoprostheses, has been the subject of many international series, but only a few publications mention the functionality in a Bulgarian patient group.
Aim: The aim of the present study was to analyze the functional outcome in a Bulgarian group of patients with malignant bone tumors that underwent resection and reconstruction with modular tumor endoprostheses.
Materials and methods: Our series consists of 14 patients with malignant bone tumors who underwent limb salvage surgery and reconstruction with modular tumor endoprostheses between February 2012 and January 2021. Staging was done using the AJCC staging system for bone sarcoma. The MSTS score system was used to evaluate the functional results.
Results: The mean follow-up time was 38.5 months (range, 8 to 96). The mean MSTS score for our series was 70%. Distant metastases were found in 4 (28%) patients. Local recurrence occurred in 3 (21%) patients. The most severe late complication was a mechanical failure of the expanding mechanism in 1 patient.
Conclusions: Reconstruction with modular tumor endoprostheses offer superb functionality and improved life quality in patients with primary malignant bone tumors.
endoprostheses, limb salvage, reconstructive surgical procedures, sarcoma
Primary malignant bone tumors (PMBT) account for 0.2% of all malignancies in adults and 3-6% in pediatric patients.[
In the present day, more than 85% of patients with PMBT can undergo some form of limb salvage surgery.[
The aim of our study was to analyze the functional outcome in a Bulgarian group of patients with PMBT who underwent limb salvage surgery and reconstruction with modular tumor endoprostheses.
this study was conducted at Prof. Boycho Boychev University Orthopedic Hospital, in the Department of Orthopedics and Traumatology of the Medical University of Sofia. Our series consists of 14 patients with PMBT who underwent limb salvage surgery and reconstruction with modular tumor endoprostheses in the mentioned institution between February 2012 and January 2021. The diagnosis was Ewing’s sarcoma in 7 patients, osteosarcoma in 4 patients, malignant giant cell tumor of the bone in 1 patient, mesenchymal chondrosarcoma in 1 patient, and malignant chondroblastoma in 1 patient. Our series consists of 10 males and 4 females, with a mean age of 20.5 years (range 13 to 71 years). Localizations of the primary tumor include the humerus, tibia, and femur, the most common being the distal femur.[
For staging, we used the AJCC staging system for bone sarcoma, which is based on 4 key aspects of the tumor: T – size of the tumor, N – lymph node involvement, M – distant metastases, and G – histological grade of the tumor.[
A 13-year-old male patient with osteosarcoma in the proximal humerus stage ⅡB (A,B). Reconstruction was done with a total humerus modular mega-endoprosthesis (C,D). MSTS score – 63%.
A, B. A 14-year-old male after reconstruction with a conventional modular tumor endoprosthesis. MSTS score – 60%. C. A 13-year-old male patient with mesenchymal chondrosarcoma of the proximal femur stage Ⅲ, reconstruction with a total femur expandable endoprosthesis, MSTS score – 73%. D. A 14-year-old female patient with malignant chondroblastoma of the distal femur stage ⅡA. Reconstruction was done with an expandable tumor endoprosthesis. MSTS score – 73%.
For functional assessment of the patients after surgery we used the MSTS score system for upper and lower extremity.[
The mean follow-up time was 38.5 months (range 8 to 96). A total of 17 operative procedures were conducted, 3 of which were secondary revisional surgeries.
Eleven (78%) of our 14 patients were evaluated as stage Ⅱ on the AJCC staging system, 6 of them being stage ⅡA and 5 – stage ⅡB. Two of the patients (15%) were stage Ⅳ, one of them stage ⅣA, and one stage ⅣB. Only one patient was evaluated as being stage Ⅲ. Distant metastases were found in 4 (28%) patients, as the most common localization were the lungs. Local recurrence occurred in a total of 3 (21%) patients and one of those cases required a secondary ablative surgery for its management. Two patients died from complications associated with the disease during the follow-up period.
The mean MSTS score for our series was 70%. Patients with distal femur reconstruction had an MSTS score between 63 and 83%. Two of the patients with a proximal humerus endoprosthesis had an MSTS score of 63 and 76%, respectively. Our only patient with a proximal femur reconstruction had an MSTS score of 53%. All five of the patients with an expandable endoprosthesis had very good functionality with a mean MSTS score of 73%.
The most common early complication in our series was surgical wound necrosis and dehiscence, which was reported in three of the patients. Peripheral nerve palsy was encountered in one patient and was successfully treated with conservative methods. The most severe late complication was a mechanical failure of the expanding mechanism in 1 patient, and although not life threatening, it caused the development of a limb length discrepancy. This complication occurred two consecutive times in a single year and required two revisional surgeries for its management. The other late complication that we encountered was an aseptic loosening of the femoral stem of the modular endoprosthesis in 1 patient, which was diagnosed 1 year after reconstruction. A revisional surgery was done and the femoral stem was replaced with a longer one.
The main advantage of modular tumor endoprostheses comes from their modular design, which allows the surgical team to adjust the length of bone resection intraoperatively and gives them the freedom to achieve a wide resection of the tumor especially in cases in which tumor infiltration is more severe than that seen on the preoperative imaging studies. Unlike biological reconstruction methods, modular tumor endoprostheses offer lower risk of deep infections and completely avoid any risk of non-union, disease transmission, and immune response. Patients with this type of reconstruction can start rehabilitation and weight bearing as early as the next day after the procedure. Expandable tumor endoprostheses are also modular and were designed to prevent limb length discrepancy in pediatric patients who underwent limb salvage surgery for malignant bone tumors. The expandable endoprosthesis that we used in our series is MUTARS® Xpand, the lengthening of which is based on a “growing” intramedullary nail or “FITBONE®”.[
Early complications after reconstruction with a modular tumor endoprosthesis include wound necrosis, peripheral nerve damage, infection, and thromboembolic incidents.[
Endoprosthesis survival rates and overall reconstruction longevity vary by anatomic site. Pala et al. reported an overall prosthesis survival rate of 70% at 4 years and 58% at 10 years.[
The functional results after reconstruction with modular tumor endoprostheses are generally positive. According to most literature sources, the mean MSTS score value is between 60 and 90.[
Atalay et al. compare the functional levels of patients with a conventional total hip endoprosthesis and those with a tumor hip endoprosthesis.[
The mean MSTS score and overall functional results in our patient group were very good and comparable to those of other authors (Table
Comparison between our functional results and those of other large series with these types of reconstruction
Number of patients | Mean follow-up | Mean MSTS score | |
Ivanov et al.(present study) | 14 | 38.5 months | 70% |
Gosheger et al.[ |
250 | 45 months | 70% |
Rougraf et al.[ |
73 | 144 months | 77% |
Gilg et al.[ |
50 | 64 months | 86% |
Pala et al.[ |
223 | 24 months | 81% |
Torner et al.[ |
7 | 65.3 months | 86% |
As for the complications until now, we have encountered only 2 severe ones that required surgical management. The misuse of the impulse transmitter for the expanding endoprosthesis was probably the reason for the mechanical failure of the expanding mechanism, which required replacement in one of our patients. The aseptic loosening of the femoral component that we encountered was caused by a shorter femoral stem that was used in the initial reconstruction. To lower the risk of these complications, a proper diameter and length of the femoral stem should always be used.
The limitations of the study are the short follow-up period and the small patient group, which did not allow for a more in-depth analysis of the late complications, the secondary surgeries needed for their management and for the conversion from an expandable to a conventional modular endoprosthesis at skeletal maturity in some patients. All the mentioned conditions cause a significant impact on the end functional results. The strict follow-up of the patients will continue, as some of them will soon need conversion surgery.
Reconstruction with modular tumor endoprostheses offers superb functionality and improved life quality in patients with primary malignant bone tumors.
This study is part of the National Scientific Program “Young Scientists and Postdoctoral researchers”, The ‘Young Scientists’ Module, Medical University of Sofia, Medical Faculty, No. D – 39/ 01.03.2021
The authors have declared that no competing interests exist.
The authors have no support to report.